Bioanalytical Method Development and Validation: Principles, Regulatory Frameworks, Techniques, and Emerging Trends

Abstract

Bioanalysis represents a cornerstone discipline within pharmaceutical sciences, dedicated to the qualitative and quantitative determination of drugs, metabolites, biomarkers, and endogenous compounds across diverse biological matrices including plasma, serum, urine, saliva, and tissues. The generation of accurate and reliable bioanalytical data is indispensable for drug discovery, preclinical evaluation, clinical development, therapeutic drug monitoring, bioavailability, bioequivalence, and regulatory submissions. Over time, bioanalytical methodologies have undergone significant evolution, progressing from conventional chromatographic techniques to advanced analytical platforms such as liquid chromatography–tandem mass spectrometry (LC–MS/MS), highresolution mass spectrometry (HRMS), and ligand-binding assays (LBAs). Method development encompasses systematic optimization of sample preparation, chromatographic separation, detection systems, and analytical conditions to ensure robust and reproducible performance. Validation of bioanalytical methods is a critical process that establishes reliability, accuracy, precision, selectivity, sensitivity, recovery, stability, and reproducibility, thereby confirming suitability for regulatory and scientific applications. International regulatory authorities, including the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), the World Health Organization (WHO), and the International Council for Harmonisation (ICH), have issued comprehensive guidelines to standardize validation practices, with the ICH M10 guideline providing a globally harmonized framework. Despite remarkable technological advancements, persistent challenges such as matrix effects, analyte instability, limited sample volumes, and the increasing complexity of biologics continue to shape bioanalytical research. Recent innovations—including ultra-performance liquid chromatography (UPLC), micro sampling technologies, automation, artificial intelligence, and biomarker-driven analysis—have expanded analytical capabilities, improved efficiency, and broadened the scope of bioanalysis. This review offers a comprehensive synthesis of bioanalytical method development, validation principles, regulatory frameworks, prevailing challenges, and emerging trends, underscoring the pivotal role of bioanalysis in contemporary drug development and personalized medicine